Blood Screening Market by Technology (Nucleic Acid Testing (NAT), Elisa, Rapid Tests, Western Blot Assay, and Next-generation Sequencing (NSG)), Product (Reagents & Kits, Instruments, and Software & Services), and End User (Blood Banks and Hospitals) - Global Opportunity Analysis and Industry Forecast, 2021-2027
|ID: VPR/HC/148||Publishing Year: January 2021||Pages: 105||Format:|
The Blood Screening Market was valued at $XXX billion in 2019, and it is expected to reach $XX billion by 2027, registering a CAGR of XX% from 2021 to2027.
A Blood Screening is a medical procedure in which blood is examined for a particular disease or medical condition. It helps to monitor diseases and prevent health problems and a variety of other conditions such as infections. Human Immunodeficiency Virus (HIV), blood type, pregnancy screenings and hypothyroidism are the most common types of Blood Screening Tests. Blood Donor Screening is the mechanism for protection against the spread of infection prior to Blood Donation. A number of Blood Screenings are performed in labs before Blood or Blood Products are transfused. In addition, blood is cautiously screened for serious diseases or infections when it donated to blood banks.
Increasing number of Blood Donations and Blood Donors, growing awareness regarding maintaining of safety of donated blood, increasing occurrence of contagious diseases, demand for donated blood and rising initiatives by governments are some of the key factors driving the growth of the global blood screening market. On the other hand, growing healthcare sector along with rising of technological advancement will further boost numerous opportunities that will also lead to the growth of the Blood Screening Market. However, complex monitoring for approval, lack of skilled manpower, presence of substitute technologies, high initial capital expenditure and operating costs of testing are the major limiting factors for the growth of the Blood Screening Market.
The Blood Screening Market is segmented by Technology, Product and End User.
On the basis of technology, the Blood Screening Market is segmented into Nucleic Acid Testing (NAT), Elisa, Rapid Tests, Western Blot Assay, and Next-generation Sequencing (NSG). Nucleic acid amplification test (NAT) is expected to rise at the fastest rate due to its high sensitivity and specificity for viral nucleic acid. The test detects nucleic acid prior than other screening methods and, thus, narrows the window period of HBV, HCV, and HIV infections. ELISA is accounted the second largest share of the market. The growth of this technology is attributed to constant development to increase its specificity, low cost as compared to NAT, There are various ELISA generations available in the market such as the first-generation ELISA, second-generation ELISA, third-generation ELISA and fourth-generation and so on.
On the basis of product the Blood Screening Market id segmented into Reagents & Kits, Instruments, and Software & Services. Reagents and kits give Higher accuracy and specificity in detecting presence and type of various elements. They are also cost-effective for customers and give a high return on investment to the vendors. High cost and reusable nature of instruments restrict the growth of instrument segment in the Blood Screening Market.
End User Insights:
The end user in the Blood Screening Market is segmented into diagnostic centers, blood bank, hospitals, clinics and ambulatory surgical centers etc. The blood is collected by the blood donors for the Screening process.
Major Key Players of Global Blood Screening Market:
The report provides a comprehensive analysis of the key players operating in the global Blood Screening Market, such as Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Ortho Clinical Diagnostics, Danaher Corporation, Abbott Laboratories, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Grifols, Siemens AG, and Beckman Coulter, Inc. Most of the key players in Blood Screening are focusing on business expansion to gain a higher revenue share through the adoption of strategies, such as mergers and acquisitions and new product development.
Blood Screening Market Key Segments:
- Nucleic Acid Testing (NAT)
- Transcription Mediated Amplification (TMA)
- Real-time PCR
- First Generation
- Second Generation
- Third Generation
- Fourth Generation and above
- Rapid Tests
- Western Blot Assays
- Next Generation Sequencing (NGS)
- Reagents & Kits
- Software & Services
By End User:
- Blood Banks
- North America
- Rest of Europe
- Rest of Asia-Pacific
- South Africa
- Saudi Arabia
- Rest of LAMEA
Frequently Asked Questions
Type Here for table of content.